Elagolix to medically treat a uterine adenomyoma: a case report

We report a case which, to our knowledge, is the first report of the gonadotropin releasing hormone (GnRH)-antagonist elagolix having a debulking effect on a uterine adenomyoma. Adenomyosis of the uterus, the presence of endometrial glands and stroma within myometrial tissues, may manifest as diffuse uterine adenomyosis in which case endometrial cells are interspersed within the myometrium, or as the uterine adenomyoma which is a focal uterine mass comprised of adenomyotic cells [1]. Medical management of uterine adenomyoma follows the same rationale as medical management of endometriosis, whereby endometriotic cell proliferation is suppressed by decreasing estradiol levels, by increasing progestin levels, or a combination thereof.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Correspondence Source Type: research